IPG Investment Advisors’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

IPG Investment Advisors’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-28,700	Closed	-$864	–	184
2022 Q4	$864	Hold	28,700	–	–	﹤0.01%	140
2022 Q3	$5.05K	Sell	28,700 -200	-0.7%	-$204	﹤0.01%	143
2022 Q2	$17K	Hold	28,900	–	–	﹤0.01%	153
2022 Q1	$38K	Hold	28,900	–	–	0.01%	162
2021 Q4	$76K	Buy	+28,900	New	+$87.3K	0.01%	194

IPG Investment Advisors's PHAS Position: Q1 2023 in Review

IPG Investment Advisors sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q1 2023, closing a stake of 28,700 shares — an estimated $864 sold.

IPG Investment Advisors first reported a position in PHAS in Q4 2021 and held it in 5 quarters. The position peaked at $76K in Q4 2021. 0 funds tracked by Wall St. Rank hold PHAS as of Q1 2023.

IPG Investment Advisors reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
IPG Investment Advisors sold 28,700 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $864.
IPG Investment Advisors first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 5 quarters.
IPG Investment Advisors's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $76K in Q4 2021.
0 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on IPG Investment Advisors's 13F filing for Q1 2023, filed 12 May 2023.